covid-19

XENOTHERA therapeutic farm, unique in France and across Europe, is featured in a major report published by Les Échos Week-End on April 24, 2026

Our 500 animals are raised under exceptional sanitary conditions, with one ambition: paving the way for animal-to-human organ transplantation. The report highlights the concrete challenges of xenotransplantation in France. It also showcases what XENOTHERA, at the heart of the XENOCURE consortium, is already developing today, notably its LIS1 antibody, administered during allografts to neutralize the immune system’s immediate response. It has received orphan drug designation in both the United States and Europe.

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

[Press Alert] XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1variant.

December 19, 2022. # Download our press alert (english version) # Télécharger...

[Newsletter] XENONEWS

November 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

[Press Alert] XENOTHERA, Nantes University Hospital and the University of Nantes announce the signature of a consortium agreement within the framework of PSPC-COVID.

July 15, 2020. # Download our press release (english version) # Télécharger...

XENOTHERA therapeutic farm, unique in France and across Europe, is featured in a major report published by Les Échos Week-End on April 24, 2026

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

[Press Alert] XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1variant.

[Newsletter] XENONEWS

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

[Newsletter] XENONEWS

[Press Information] XENOTHERA presents LIS1 results at the American Transplant Congress (ATC) in Boston

[Press Alert] Safety and efficacy results of LIS1

[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.

[Newsletter] XENONEWS

[Newsletter] XENONEWS

[Newsletter] XENONEWS

[Press Alert] Omicron Variant : positive results for XENOTHERA's XAV-19 antibody

[Infography/Infographie] Covid19

[Press Alert] XENOTHERA, Nantes University Hospital and the University of Nantes announce the signature of a consortium agreement within the framework of PSPC-COVID.

[Newsletter - 8] NEWS/INFOS

[Newsletter - 7] NEWS/INFOS

[Alerte actualité] Financement XENOTHERA

[Newsletter-5] NEWS/INFOS

In the News/ A la une

[Newsletter -4] NEWS/INFOS

[Newsletter -3] NEWS/INFOS

[Newsletter -2] NEWS /INFOS

[Alerte actualité] Anticorps XAV19